XTX Topco’s Arcutis Biotherapeutics ARQT Stock Holding History

XTX Topco’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19M	Buy	45,545 +2,861	+7%	+$66.7K	0.02%	1626
2026 Q1	$1.01M	Sell	42,684 -31,674	-43%	-$808K	0.02%	1412
2025 Q4	$2.16M	Buy	74,358 +63,055	+558%	+$1.61M	0.06%	518
2025 Q3	$213K	Sell	11,303 -26,252	-70%	-$414K	0.01%	1796
2025 Q2	$527K	Sell	37,555 -36,121	-49%	-$506K	0.02%	1064
2025 Q1	$1.15M	Buy	+73,676	New	+$1.04M	0.06%	483
2024 Q4	–	Sell	-47,728	Closed	-$444K	–	2274
2024 Q3	$444K	Buy	47,728 +11,262	+31%	+$111K	0.03%	902
2024 Q2	$339K	Buy	36,466 +25,793	+242%	+$233K	0.03%	882
2024 Q1	$106K	Sell	10,673 -135,389	-93%	-$1.01M	0.01%	1354
2023 Q4	$472K	Buy	146,062 +122,602	+523%	+$333K	0.1%	295
2023 Q3	$125K	Buy	+23,460	New	+$200K	0.02%	1152
2023 Q1	–	Sell	-12,222	Closed	-$181K	–	1259
2022 Q4	$181K	Buy	+12,222	New	+$214K	0.04%	881

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

XTX Topco's ARQT Position: Q2 2026 in Review

XTX Topco increased its Arcutis Biotherapeutics (ARQT) stake by 6.7% in Q2 2026, buying an estimated $66.7K and bringing the position to 45,545 shares worth $1.19M. The position accounts for 0.02% of the portfolio, ranked #1626.

XTX Topco first reported a position in ARQT in Q4 2022 and has held it in 12 quarters since. The position peaked at $2.16M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

XTX Topco held 45,545 shares of Arcutis Biotherapeutics worth $1.19M as of Q2 2026.
XTX Topco bought 2,861 Arcutis Biotherapeutics shares in Q2 2026, an estimated $66.7K.
Arcutis Biotherapeutics made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1626 holding.
XTX Topco first reported a position in Arcutis Biotherapeutics in Q4 2022 and has held it in 12 quarters since.
XTX Topco's Arcutis Biotherapeutics position peaked at $2.16M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.